logo-loader
THC Global Group Ltd

THC Global eyes CBD opportunities in New Zealand underpinned by easier access for patients

New Zealand has, proportionally, a far larger immediately accessible patient population compared to Australia given the regulatory hurdles for supply of medicinal cannabis to patients in Australia.

THC Global Group Ltd - THC Global eyes CBD opportunities in New Zealand underpinned by easier access for patients
THC’s shipment of products recently landed in NZ and initial sales have been positive

THC Global Group Ltd (ASX:THC) is continuing to progress its exclusive distribution of Endoca CBD (cannabidiol) products in New Zealand with shipment of products recently landed.

Access to CBD products in New Zealand is relatively straightforward, with patients able to seek a prescription for CBD products just as they can for any other prescription medicine without the need for government approvals on a case-by-case basis as was previously required.

As a result, New Zealand has, proportionally, a far larger immediately accessible patient population compared to Australia given the regulatory hurdles for supply of medicinal cannabis to patients in Australia.

CBDinfo.co.nz

In order to provide prescribers with the best available information on CBD products to assist in making decisions on prescribing them to patients, THC provided financial assistance to DATAPHARM, a healthcare company in New Zealand, to launch CBDinfo.co.nz.

CBDinfo is a platform providing medical practitioners relevant and evidenced information about the use, availability, and potential benefits and risks of using CBD products.

Since launch in June 2019, over 100 medical practitioners have enrolled.

Once enrolled, practitioners can access detailed information on efficacy and safety data, as well as details on how to prescribe CBD products.

Initial sales have been positive

THC’s import and distribution process makes Endoca products available to all wholesalers in New Zealand, rather than a specialised subset or specific region.

Initial sales levels have been positive, supporting THC’s focus on doctor education and information provision as a means of responsibly supporting medical professionals and patients in the use of CBD.

The supply pathways and prescriber engagement and education activities THC has developed with the distribution of the Endoca product range will allow for THC to enter the New Zealand market with its own Australian produced medicine range next year.

THC’s medicine range for export next year will be pharmaceutical Good Manufacturing Practice (GMP) certified medicines produced from its Southport Manufacturing Facility.

Quick facts: THC Global Group Ltd

Price: 0.415 AUD

Market: ASX
Market Cap: $56.72 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of THC Global Group Ltd named herein, including the promotion by the Company of THC Global Group Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: THC Global receives final licences and will complete product...

THC Global Group Ltd (ASX:THC) chief executive officer Ken Charteris updates Proactive on receiving the final licences required for Australian production and distribution of narcotic medicines, including medicinal cannabis, for the recently opened Southport and Bundaberg manufacturing facilities...

1 week, 6 days ago

2 min read